SG11201609830RA - 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors - Google Patents

5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors

Info

Publication number
SG11201609830RA
SG11201609830RA SG11201609830RA SG11201609830RA SG11201609830RA SG 11201609830R A SG11201609830R A SG 11201609830RA SG 11201609830R A SG11201609830R A SG 11201609830RA SG 11201609830R A SG11201609830R A SG 11201609830RA SG 11201609830R A SG11201609830R A SG 11201609830RA
Authority
SG
Singapore
Prior art keywords
chloro
jak inhibitors
pyrazolopyrimidine compounds
difluoromethoxyphenyl pyrazolopyrimidine
difluoromethoxyphenyl
Prior art date
Application number
SG11201609830RA
Inventor
Mark Edward Zak
Nicholas Charles Ray
Simon Charles Goodacre
Rohan Mendonca
Terry Kellar
Yun-Xing Cheng
Wei Li
Po-Wai Yuen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201609830R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201609830RA publication Critical patent/SG11201609830RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201609830RA 2014-05-23 2015-05-22 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors SG11201609830RA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462002547P 2014-05-23 2014-05-23
US201562101234P 2015-01-08 2015-01-08
US201562130098P 2015-03-09 2015-03-09
CNPCT/CN2015/077176 2015-04-22
PCT/EP2015/061350 WO2015177326A1 (en) 2014-05-23 2015-05-22 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors

Publications (1)

Publication Number Publication Date
SG11201609830RA true SG11201609830RA (en) 2016-12-29

Family

ID=53276096

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609830RA SG11201609830RA (en) 2014-05-23 2015-05-22 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors

Country Status (20)

Country Link
US (5) US9346815B2 (en)
EP (1) EP3145929B1 (en)
JP (2) JP2017516850A (en)
KR (1) KR20170005870A (en)
CN (2) CN106459039A (en)
AU (3) AU2015261812B2 (en)
CA (1) CA2948589A1 (en)
CL (1) CL2016002877A1 (en)
EA (1) EA032488B1 (en)
HR (1) HRP20210935T1 (en)
HU (1) HUE054784T2 (en)
IL (2) IL248661B (en)
MX (1) MX2016015062A (en)
PE (2) PE20170663A1 (en)
PH (1) PH12016502099A1 (en)
SG (1) SG11201609830RA (en)
SI (1) SI3145929T1 (en)
TW (1) TWI699364B (en)
UA (1) UA121658C2 (en)
WO (1) WO2015177326A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459039A (en) * 2014-05-23 2017-02-22 豪夫迈·罗氏有限公司 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
EP3200589A4 (en) 2014-09-10 2018-07-25 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
WO2016183150A1 (en) * 2015-05-12 2016-11-17 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
TW201720828A (en) * 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 Therapeutic compounds and compositions, and methods of use thereof
WO2017103188A1 (en) * 2015-12-18 2017-06-22 F. Hoffmann-La Roche Ag Therapeutic compounds, compositions and methods of use thereof
CN108473501B (en) * 2016-02-18 2021-07-16 豪夫迈·罗氏有限公司 Therapeutic compounds, compositions and methods of use thereof
AU2017385543A1 (en) 2016-12-29 2019-05-23 F. Hoffmann-La Roche Ag Pyrazolopyrimidine compounds and methods of use thereof
CN110494434B (en) * 2017-03-14 2022-05-24 豪夫迈·罗氏有限公司 Pyrazolophenyl compounds, compositions thereof, and methods of use thereof
EP3630767A1 (en) 2017-05-22 2020-04-08 H. Hoffnabb-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
BR112019024322A2 (en) * 2017-05-22 2020-06-16 F. Hoffmann-La Roche Ag THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND METHODS OF USE THEREOF
IL273924B2 (en) 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
US11352344B2 (en) 2017-10-31 2022-06-07 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
WO2019139714A1 (en) 2018-01-15 2019-07-18 Genentech, Inc. Pyrazolopyrimidine compounds as jak inhibitors
WO2019152809A1 (en) * 2018-02-02 2019-08-08 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
AU2019241260B2 (en) * 2018-03-28 2022-06-16 Fochon Biosciences, Ltd. Macrocyclic compounds as TRK kinases inhibitors
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP7455810B2 (en) 2019-03-13 2024-03-26 大塚製薬株式会社 Method for introducing deuterated lower alkyl into the amine moiety of a compound containing a secondary amine
WO2020257143A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
MA56518A (en) 2019-06-18 2022-04-27 Hoffmann La Roche JAK KINASES PYRAZOLOPYRIMIDINE SULPHONE INHIBITORS AND THEIR USES
CN114026096A (en) * 2019-06-18 2022-02-08 豪夫迈·罗氏有限公司 Tetrazole-substituted pyrazolopyrimidine JAK kinase inhibitor and application thereof
WO2022059779A1 (en) 2020-09-18 2022-03-24 大日本住友製薬株式会社 Amine derivative
WO2022251533A1 (en) * 2021-05-27 2022-12-01 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2022256358A1 (en) 2021-06-03 2022-12-08 Genentech, Inc. Process for preparing medicaments

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES517193A0 (en) 1981-11-10 1983-12-01 Wellcome Found A PROCEDURE FOR THE PREPARATION OF NEW IMIDAZO DERIVATIVES (4,5-C) PIRIDINA.
US4847256A (en) 1986-10-16 1989-07-11 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5705625A (en) 1994-12-15 1998-01-06 The Johns Hopkins University School Of Medicine Nucleic Acid Encoding novel protein tyrosine kinase
US7070972B1 (en) 1995-01-13 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Janus family kinases and identification of immune modulators
US7091020B1 (en) 1995-12-05 2006-08-15 Incyte Corporation Human Jak2 kinase
ID18494A (en) 1996-10-02 1998-04-16 Novartis Ag PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
FR2791562B1 (en) 1999-03-29 2004-03-05 Oreal TINCTORIAL COMPOSITION CONTAINING PYRAZOLO- [1,5-A] - PYRIMIDINE AND A MONOCYCLIC POLYAMINOPYRIMIDINE AS OXIDATION BASES AND A COUPLER, AND DYEING METHODS
CA2376835C (en) 1999-07-02 2009-09-15 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
JP4078074B2 (en) 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク Pyrrolo [2,3-d] pyrimidine compound
BR0309475A (en) 2002-04-23 2005-03-01 Shionogi & Co Pyrazolo [1,5-a] pyrimidine derivatives and nad (p) h oxidase inhibitors containing them
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
US20070270408A1 (en) 2003-04-11 2007-11-22 Novo Nordisk A/S Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
US7393873B2 (en) 2003-07-02 2008-07-01 Merck & Co., Inc. Arylsulfonamide derivatives
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US20060030536A1 (en) 2004-04-09 2006-02-09 University Of South Florida Combination therapies for cancer and proliferative angiopathies
WO2005105803A2 (en) 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
MXPA06014637A (en) 2004-06-25 2007-02-12 Amgen Inc Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases.
DK1812440T3 (en) 2004-11-04 2011-01-31 Vertex Pharma Pyrazolo [1,5-a] pyrimidines which can be used as inhibitors of protein kinases
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
WO2007039797A1 (en) 2005-10-03 2007-04-12 Pfizer Products Inc. Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis
US7645762B2 (en) 2005-10-06 2010-01-12 Schering Corporation Substituted pyrazolo[1,5-a] pyrimidines as protein kinase inhibitors
ATE517874T1 (en) 2005-10-21 2011-08-15 Exelixis Inc PYRIMIDINONES AS MODULATORS OF CASEINKINASE II (CK2)
JP2009518340A (en) 2005-12-08 2009-05-07 ノバルティス アクチエンゲゼルシャフト Pyrazolo [1,5-a] pyridine-3-carboxylic acid as an EphB and VEGFR2 kinase inhibitor
US8541406B2 (en) 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AR061793A1 (en) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp PIRAZOLO COMPOUND [1,5-A] PYRIMIDINE AND PHARMACEUTICAL COMPOSITION
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (en) 2006-07-14 2008-04-25 Amgen Inc FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
CA2670083A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CN104151293A (en) 2007-10-12 2014-11-19 阿斯利康公司 Inhibitors of protein kinases
EP3912973A3 (en) 2007-11-28 2022-02-16 Dana-Farber Cancer Institute, Inc. Small molecule myristate inhibitors of bcr-abl and methods of use
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester Method for altering the lifespan of eukaryotic organisms
CA2712507A1 (en) * 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
US20110224080A1 (en) 2008-07-02 2011-09-15 Antonio Lelas Formulation based on micronized natural calcite mineral and micronized zeolite as an enhanced plant booster and mineral fertilizer
WO2010019762A1 (en) 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
PE20131197A1 (en) * 2008-10-31 2013-11-06 Genentech Inc PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
US8946426B2 (en) 2009-02-06 2015-02-03 Janssen Pharmaceuticals, Inc. Substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (en) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
NZ598907A (en) 2009-10-20 2014-03-28 Cellzome Ltd Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
MX2012010265A (en) 2010-03-17 2012-10-01 Hoffmann La Roche Imidazopyridine and purine compounds, compositions and methods of use.
EA201291038A1 (en) 2010-04-30 2013-05-30 Целльзом Лимитид PYRAZOL COMPOUNDS AS JAK INHIBITORS
KR20190077610A (en) 2010-07-13 2019-07-03 에프. 호프만-라 로슈 아게 Pyrazolo[1,5a]pyrimidine and thieno[3,2b]pyrimidine derivatives as irak4 modulators
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
WO2012129258A1 (en) * 2011-03-22 2012-09-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN106459039A (en) * 2014-05-23 2017-02-22 豪夫迈·罗氏有限公司 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
EP3268004B1 (en) 2015-03-12 2019-12-18 Merck Sharp & Dohme Corp. Pyrrolopyridazine inhibitors of irak4 activity
WO2016144848A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrrolotriazine inhibitors of irak4 activity
WO2016144846A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
EP3268367B8 (en) 2015-03-12 2022-11-16 Merck Sharp & Dohme LLC Carboxamide inhibitors of irak4 activity

Also Published As

Publication number Publication date
EP3145929B1 (en) 2021-01-13
PE20211782A1 (en) 2021-09-08
IL248661B (en) 2019-10-31
TW201607948A (en) 2016-03-01
US20150336962A1 (en) 2015-11-26
PE20170663A1 (en) 2017-05-22
TWI699364B (en) 2020-07-21
US20160237086A1 (en) 2016-08-18
AU2015261812B2 (en) 2019-11-21
JP2017516850A (en) 2017-06-22
US20180305355A1 (en) 2018-10-25
UA121658C2 (en) 2020-07-10
EA032488B1 (en) 2019-06-28
US20170145020A1 (en) 2017-05-25
KR20170005870A (en) 2017-01-16
US9346815B2 (en) 2016-05-24
JP2020164542A (en) 2020-10-08
IL268446A (en) 2019-09-26
SI3145929T1 (en) 2021-10-29
WO2015177326A1 (en) 2015-11-26
AU2015261812A1 (en) 2016-11-24
EA201692338A1 (en) 2017-04-28
CL2016002877A1 (en) 2017-06-09
CN109970743A (en) 2019-07-05
HUE054784T2 (en) 2021-09-28
EP3145929A1 (en) 2017-03-29
CA2948589A1 (en) 2015-11-26
IL248661A0 (en) 2017-01-31
CN106459039A (en) 2017-02-22
AU2019257450A1 (en) 2019-11-21
US9604984B2 (en) 2017-03-28
HRP20210935T1 (en) 2021-08-06
MX2016015062A (en) 2017-02-27
PH12016502099A1 (en) 2017-01-09
JP7041198B2 (en) 2022-03-23
US20190322661A1 (en) 2019-10-24
CN109970743B (en) 2022-03-04
AU2021203734A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
IL268446A (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
IL250709B (en) Aminopyrimidinyl compounds as jak inhibitors
PL3248980T3 (en) Jak inhibitor
AP2017009836A0 (en) Aminopyridyloxypyrazole compounds
GB201415573D0 (en) Compounds
SG11201610904UA (en) Syk inhibitors
GB201411418D0 (en) Compounds
HUE053463T2 (en) Pyrrolopyrimidine compounds useful as jak inhibitors
GB201410430D0 (en) Compounds
EP3183255C0 (en) Spiropyrrolidines as mdm2 inhibitors
GB201402431D0 (en) Compounds
GB201403536D0 (en) Inhibitor compounds
GB201404987D0 (en) Compounds
GB201406956D0 (en) Compounds
GB201406591D0 (en) Compounds
AP2017009778A0 (en) Azetidinyloxyphenylpyrrolidine compounds
GB201412660D0 (en) Compounds
GB201407695D0 (en) Compounds
GB201405361D0 (en) Compounds
GB201416116D0 (en) Compounds
GB201415571D0 (en) Compounds
GB201415570D0 (en) Compounds
GB201413524D0 (en) Compounds
GB201413527D0 (en) Compounds
GB201411402D0 (en) Compounds